E. Therrien

发表

Abstract 3327: Discovery and characterization of the potent, allosteric SHP2 inhibitor GDC-1971 for the treatment of RTK/RAS driven tumors

D. Bergstrom, M. Murcko, D. Shaw, 2022, Cancer Research.